Company intelligence / Profile preview
Vernagen
Atlanta, Georgia, United Statesvernagen.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vernagen is developing mRNA-based vaccines and therapeutic biologics; its pipeline of prophylactic mRNA vaccines for multiple infectious diseases is currently in discovery and preclinical stages, with no clinical trial results reported yet.[1][6]
- Therapeutic areas
- ImmunologyRare DiseasesInfectious Diseases
- Modalities
- mRNA-based drugsVaccineBiologic
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
ST Pharm (mRNA Center collaboration in global R&D; Vernagen listed as partner in innovative RNA therapeutics and mRNA cancer vaccines/therapeutics initiative)[4]
Beyond the preview
Go deeper on Vernagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vernagen.